CAMP4 Therapeutics (NASDAQ:CAMP) Share Price Crosses Above 200 Day Moving Average – Here’s Why

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.66 and traded as high as $4.70. CAMP4 Therapeutics shares last traded at $4.51, with a volume of 76,188 shares trading hands.

Analyst Upgrades and Downgrades

CAMP has been the topic of a number of research analyst reports. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Finally, Leerink Partners boosted their target price on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, April 2nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.60.

CAMP4 Therapeutics Stock Up 2.5%

The business’s 50 day simple moving average is $4.56 and its two-hundred day simple moving average is $4.66. The stock has a market cap of $234.19 million, a P/E ratio of -1.91 and a beta of 0.04.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The firm had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, research analysts forecast that CAMP4 Therapeutics Corporation will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in CAMP4 Therapeutics in the 4th quarter valued at approximately $61,000. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at approximately $70,000. State Street Corp increased its position in CAMP4 Therapeutics by 52.7% in the 4th quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock valued at $243,000 after acquiring an additional 13,700 shares during the period. Bank of America Corp DE bought a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at $86,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of CAMP4 Therapeutics during the fourth quarter worth $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.